Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of JNJ-54416076 in Healthy Males
NCT02670395Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing JNJ-54416076 with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events, Time To Reach The Maximum Observed Concentration and 7 more. Started Apr 2016; status: completed.
02
Drugs
JNJ-54416076
Beyond the preview
Go deeper on NCT02670395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670395.